$LILA

Liberty Latin America Director De Angoitia Buys $10 Million Shares. What Does This Large Purchase Mean for Investors?

Liberty Latin America director Alfonso De Angoitia bought 476,000 Series A Preference Shares at $20.95 each, totaling $10 million. The purchase was made through Grenadier S.A., an entity he owns. The company has a market cap of $1.7 billion and reported $4.5 billion in TTM revenue. The shares have appreciated 80.79% over the past year.

Original reporting
Published Sep 8, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Liberty Latin America Director De Angoitia Buys $10 Million Shares. What Does This Large Purchase Mean for Investors? — source image
Decision brief

The 30-second read

$LILABullishMed
01

Why it matters

The insider purchase adds a bullish catalyst to the stock, potentially supporting price appreciation, especially given the premium paid over market price.

02

Market read

Insider buying is a classic positive signal; the size and premium of this transaction make it noteworthy for traders.

03

What to watch

Preference shares have a liquidation value and high dividend yield, making them more bond‑like; the buy may reflect yield seeking rather than equity upside.

Relevance 6/10Novelty 8/10Timing: today

Background

Liberty Latin America (LILA) is a telecom operator serving Caribbean and Latin American markets, with a market cap of ~$2.6 B.

Company-level read

Ticker impact

$LILABullishHigh confidence
Context

Director Alfonso De Angoitia purchased ~476,000 Series A Preference Shares (~$10M) in a Form 4 filing, indicating a significant insider buy.

Expected impact

Potential modest upside over the next few weeks as market digests the bullish signal.

Evidence & confidence

The purchase price ($20.95) is well above the current market price, indicating strong conviction; insider buys of this size historically correlate with positive price moves.

Market effects

May boost sentiment for the telecom sector and other Latin American operators.

Could positively influence broader Latin American equity sentiment.

Limited to telecom and emerging market investors.

Counterpoint

The purchase could be a personal liquidity move rather than a conviction signal.

Key entities

  • Alfonso De Angoitia

    Director at Liberty Latin America and co‑CEO of Grupo Televisa.

  • Liberty Latin America

    Telecommunications provider in the Caribbean and Latin America.

Related articles

$LILAMed

Liberty Latin America (LILA) Q2 2026 Earnings Call Transcript

Liberty Latin America (LILA) reported Q2 2026 revenue of $1.1 billion (1% growth), adjusted OIBDA of $436 million (+3% rebased), and adjusted free cash flow of $83 million. Total debt was $8.5 billion, net leverage 4.6x, and cash $747 million. The company also discussed repurchases, a $500 million preferred distribution, and a 10-year Amdocs IT and AI deal.

$LILAMed

Liberty Latin America Reports Q2 2026 Results

Liberty Latin America Ltd. (LILA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liberty Latin America Reports Q2 2026 Results Gained 45,000 postpaid and broadband net adds in Q2 Operating Income & Adjusted OIBDA YoY growth Significant expansion in cash flow from operations and Adjusted FCF Completed preferred stock distribution; declared quarter

$ABBVMed

What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?

AbbVie (ABBV) and Genmab reported positive Phase 3 trial results for epcoritamab plus R-CHOP in high-risk diffuse large B-cell lymphoma, showing a 51% reduction in disease progression or death risk. The data suggest potential for front-line treatment, supporting AbbVie's oncology ambitions and revenue diversification. Regulatory filings and approvals will be key next steps.

$PRAXMed

PRAX Initiated Coverage by UBS -- Price Target Announced at $706

UBS initiated coverage on Praxis Precision Medicine (PRAX) with a 'Buy' rating and a $706 price target. The company's current price is $248.24, which is significantly higher than its GF Value of $11.67, indicating a 2027.2% overvaluation. PRAX has a GF Score of 40, reflecting concerns about its financial health and growth potential. The company is a clinical-stage biopharmaceutical firm focusing on central nervous system disorders.

$REGNMed

REGN Upgraded by UBS -- Price Target Raised to $978

UBS upgraded Regeneron Pharmaceuticals (REGN) to 'Buy' with a $978 price target, up 48.18% from $660. GuruFocus values REGN at $925.48, suggesting it's 14.0% undervalued. The company has a GF Score of 87/100, strong financials, and a market cap of $81.99B. Analysts cite growth potential and resilience in its products, like Eylea and Dupixent.